Please login to the form below

Not currently logged in


This page shows the latest cost-effectiveness news and features for those working in and with pharma, biotech and healthcare.

AbbVie preps uterine fibroid filing after phase 3 win

Neurocrine pocketed a $40m milestone payment on approval. It launched at a list price of $845 per month, above the $7, 000 annual threshold for cost-effectiveness set by the Institute

Latest news

More from news
Approximately 3 fully matching, plus 556 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Bluebird is strongly advocating an annuity-type approach – where instead of having to pay the whole cost upfront, payers can pay off the bill in yearly instalments. ... Raju Prasad says Bluebird can offer a compelling cost-effectiveness case for its

  • Shaping healthcare Shaping healthcare

    It’s a huge challenge. Germany and France aren’t easy either. They don’t do the cost-effectiveness approach, at least not with the same consequences as the UK, but ... their therapeutic effectiveness approaches also lead to very difficult

  • No incentive for a cure No incentive for a cure

    In August 2017, Novartis announced that Kymriah would be $475, 000 per treatment, which caused a lot of headlines, but was actually lower than many analysts were expecting; a cost-effectiveness ... Indeed, the cost-effectiveness evidence for many

  • Public relations

    Healthcare terms - Public relations.

  • Digital

    Healthcare terms - Digital.

More from intelligence
Approximately 0 fully matching, plus 52 partially matching documents found.

Latest appointments

  • Former NICE chair joins board of biotech Former NICE chair joins board of biotech

    The former chair of England's cost-effectiveness body for medicines, Sir Michael Rawlins, has made a contentious move to the US biotech Intra-Cellular Therapies as member of its board ... His expertise in the cost-effectiveness of new pharmaceuticals and

  • Executive changes at Teva as community and institutional affairs division launched

    Referencing Teva's previous record in compliance, Dr De Notaristefani said: “ We will continue this practice as we begin to set the industry standard for regulatory compliance, customer service and cost ... effectiveness.”. Teva launches community

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...